PEER GROUP ANALYSIS
This chart compares HQL to the highest rated funds in its peer group of Sector - Health/Biotechnology funds. The above graph illustrates two key measures that investors should consider when assessing the investment potential of a particular fund. One of the key factors is how the fund has performed over the most recent reporting period, defined as the 1 year total return on the bottom axis. The second factor is the fund's reported expense ratio, on the right axis, which includes things like management fees. The best funds, with higher returns and lower expenses, stake out a position in the lower left part of this graph.
TOP RATED FUNDS : Sector - Health/Biotechnology
|iShares US Healthcare Providers ETF||IHF||5.55||5.55||22.17||0.43||1|
|iShares US Healthcare ETF||IYH||6.08||6.08||22.48||0.43||2|
|Health Care Select Sector SPDR||XLV||6.93||6.93||22.80||0.15||3|
|iShares Global Healthcare||IXJ||7.57||7.57||18.92||0.47||4|
|Vanguard HealthCare Index ETF||VHT||6.95||6.95||23.17||0.09||5|
|iShares US Medical Devices ETF||IHI||10.75||10.75||22.31||0.43||6|
|Gabelli Healthcare & WellnessRx Tr||GRX||3.05||3.05||17.21||1.63||7|
|PowerShares DWA Healthcare Momentum||PTH||2.06||2.06||17.83||0.60||8|
|SPDR SP Intl Health Care ETF||IRY||10.22||10.22||13.76||0.44||9|
|Tekla Life Sciences Investors||HQL||5.44||5.44||26.19||1.17||17|
|The above table compares the total return performance and expense ratio of Tekla Life Sciences Investors to the top rated funds within the Sector - Health/Biotechnology peer group. Tekla Life Sciences Investors ranks number 17 out of 30 Sector - Health/Biotechnology closed-end and exchange-traded funds that we rate.|
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.